妇科肿瘤相关双特异性抗体药物

Gynecological tumor-related bispecific antibody drugs

双特异性抗体药物是近年来免疫治疗领域愈发受到关注的一种靶向治疗药物。截至发稿之日,美国食品药品监督管理局(FDA)批准上市的双特异性抗体药物仅有3种,且这3种药物均未开辟妇科肿瘤疾病的适用指征。从1997年至2020年,全球范围内先后共计有272项双特异性抗体药物的临床试验,其中约三分之一的研究是由中国贡献的,且这些临床试验大部分处于Ⅰ期(n=161)、Ⅰ/Ⅱ期(n=54)和Ⅱ期(n=51)。本文综述了妇科肿瘤相关双特异性抗体药物的作用机制及临床试验等方面的最新进展,期望更多的临床和科研工作者关注双特异性抗体药物,促进其进一步发展。

Bispecific antibody drugs are targeting therapy drugs that have attracted increasing attention in immunotherapy.Up to now,only three bispecific antibody drugs have been approved by the US Food and Drug Administration(FDA),but none of them have opened up applicable indications for gynecological tumors.From 1997 to 2020,there were a total of 272 clinical trials of bispecific antibody drugs worldwide,about one-third of which were contributed by Chinese.Most of these clinical trials were in stage Ⅰ(n=161),stageⅠ/Ⅱ(n=54) and stage Ⅱ(n=51).In this paper,we reviewed the latest progress in the mechanisms and clinical trials of bispecific antibody drugs related to gynecological tumors.It is hoped that more clinicians and researchers will pay attention to bispecific antibody drugs,and promote their development.